Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Recruiting

Phase 1

Phase 2

mRNA-4359 & PembrolizumabStudy of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

Sponsor:

Moderna

Code:

NCT05533697

Conditions

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

mRNA-4359

Pembrolizumab

Ipilimumab

Nivolumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-24. This information was provided to ClinicalTrials.gov by ModernaTX, Inc. on 2025-10-08.